Holen Sie sich die Stockscreener-App
8.56
2.15%
0.18
Schlusskurs vom Vortag:
$8.38
Offen:
$8.4
24-Stunden-Volumen:
2.20M
Relative Volume:
0.64
Marktkapitalisierung:
$1.80B
Einnahmen:
$557.51M
Nettoeinkommen (Verlust:
$-35.71M
KGV:
-47.56
EPS:
-0.18
Netto-Cashflow:
$15.50M
1W Leistung:
+2.27%
1M Leistung:
-1.04%
6M Leistung:
-7.06%
1J Leistung:
+7.94%
1-Tages-Spanne:
$8.35
$8.62
1-Wochen-Bereich:
$8.18
$8.62
52-Wochen-Spanne:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.56 | 1.76B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Quant Models Detect Momentum Reversal in BioCryst Pharmaceuticals Inc.July 2025 Trade Ideas & Technical Entry and Exit Tips - newsyoung.net
Chartists Watching For Breakout in BioCryst Pharmaceuticals Inc.2025 Technical Patterns & Verified Momentum Stock Alerts - 선데이타임즈
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript - MSN
What is BioCryst Pharmaceuticals Inc.’s TAM (Total Addressable Market)Portfolio Gains Summary & Free Weekly Chart Analysis and Trade Guides - 선데이타임즈
Is BioCryst Pharmaceuticals Inc. affected by consumer sentiment2025 Major Catalysts & Daily Price Action Insights - thegnnews.com
Is BioCryst Pharmaceuticals Inc. stock influenced by commodity pricesMarket Risk Report & Consistent Growth Stock Picks - sisa-n.com
BioCryst Director Makes a Significant Stock Sale! - TipRanks
Does BioCryst Pharmaceuticals Inc. stock reflect fundamentalsJuly 2025 Fed Impact & Daily Momentum Trading Reports - thegnnews.com
Heggie, director at Biocryst, sells $595k in shares By Investing.com - Investing.com South Africa
Heggie, director at Biocryst, sells $595k in shares - Investing.com
Why BioCryst Pharmaceuticals Inc. stock attracts strong analyst attentionWeekly Profit Analysis & Daily Profit Maximizing Trade Tips - sundaytimes.kr
Drawdown in BioCryst Pharmaceuticals Inc. May Be Nearing End2025 Bull vs Bear & Trade Opportunity Analysis - newsyoung.net
Ranking BioCryst Pharmaceuticals Inc. among high performing stocks via toolsJuly 2025 Summary & Precise Trade Entry Recommendations - Newser
Long term hold vs stop loss in BioCryst Pharmaceuticals Inc.Trend Reversal & Safe Investment Capital Preservation Plans - Newser
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN
How Efficient Is BioCryst Pharmaceuticals Inc. at Controlling Operating Costs2025 Technical Overview & High Accuracy Trade Alerts - Newser
BioCryst Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Technicals & Fast Momentum Stock Entry Tips - Newser
BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com
Are Options Traders Betting on a Big Move in BCRX Stock? - Yahoo Finance
Will BioCryst Pharmaceuticals Inc. price bounce be sustainableReal-Time Investment Picks with Accuracy - Newser
Will BioCryst Pharmaceuticals Inc. benefit from rising consumer demandStock Picks with Accelerated Return - newsyoung.net
BioCryst’s Chief R&D Officer Resigns Amid CEO Decision - The Globe and Mail
BioCryst Announces Departure of Dr. Helen Thackray - GlobeNewswire
BioCryst Announces Departure of Dr. Helen Thackray | BCRX Stock News - GuruFocus
BioCryst’s chief R&D officer to depart for CEO role elsewhere - Investing.com
BioCryst’s chief R&D officer to depart for CEO role elsewhere By Investing.com - Investing.com Canada
BioCryst's R&D Chief Departs Following CEO Race: What This Means for ORLADEYO and 2 Pipeline Drugs - Stock Titan
New Product Launches: Will They Boost BioCryst Pharmaceuticals Inc. Stock in 2025Free Technical Stock Breakout Predictions - Newser
BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome - TipRanks
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
BioCryst (BCRX) Gets a Buy from RBC Capital - The Globe and Mail
BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest
BioCryst reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Biocryst Pharmaceuticals shares rise 1.20% premarket after reporting inducement grants under Nasdaq listing. - AInvest
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Pharmaceuticals Receives Buy Rating from RBC Capital Analyst Brian Abrahams - AInvest
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals grants 36,700 shares of stock options and RSUs to new employees. - AInvest
BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks
BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
BioCryst: Q2 Earnings Snapshot - New Haven Register
BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharma Maintains Buy Rating with $17 Price Target - AInvest
BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks
BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest
BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biocryst Pharmaceuticals Inc-Aktie (BCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director |
Aug 13 '25 |
Sale |
8.51 |
70,000 |
595,868 |
65,352 |
2.37%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):